SUMAVEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sumavel, and what generic alternatives are available?
Sumavel is a drug marketed by Endo Operations and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in SUMAVEL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sumavel
A generic version of SUMAVEL was approved as sumatriptan succinate by HIKMA on February 6th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUMAVEL?
- What are the global sales for SUMAVEL?
- What is Average Wholesale Price for SUMAVEL?
Summary for SUMAVEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for SUMAVEL |
| DailyMed Link: | SUMAVEL at DailyMed |
US Patents and Regulatory Information for SUMAVEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-002 | Nov 26, 2013 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Endo Operations | SUMAVEL DOSEPRO | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 022239-001 | Jul 15, 2009 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
